[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2934 Introduced in House (IH)]
<DOC>
117th CONGRESS
1st Session
H. R. 2934
To amend title XVIII of the Social Security Act to remove from the list
of drugs excluded from coverage under the Medicare prescription drug
program prescription oral vitamins and mineral products indicated for
the treatment of iron deficiency anemia in individuals with chronic
kidney disease.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
April 30, 2021
Mr. O'Halleran (for himself, Mr. Bucshon, Mr. Butterfield, and Mr.
Mullin) introduced the following bill; which was referred to the
Committee on Energy and Commerce, and in addition to the Committee on
Ways and Means, for a period to be subsequently determined by the
Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to remove from the list
of drugs excluded from coverage under the Medicare prescription drug
program prescription oral vitamins and mineral products indicated for
the treatment of iron deficiency anemia in individuals with chronic
kidney disease.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Renal Anemia Innovation Support and
Expansion Act'' or the ``RAISE Act''.
SEC. 2. REMOVING CERTAIN PRESCRIPTION VITAMINS AND MINERAL PRODUCTS
FROM THE LIST OF DRUGS EXCLUDED FROM COVERAGE UNDER THE
MEDICARE PRESCRIPTION DRUG PROGRAM.
Section 1860D-2(e)(2)(A) of the Social Security Act (42 U.S.C.
1395w-102(e)(2)(A)) is amended by inserting ``other than subparagraph
(F) of such section (relating to prescription vitamin and mineral
products, except prenatal vitamins and fluoride preparations) if the
prescription vitamin or mineral product is orally administered and is
indicated for treatment of iron deficiency anemia in individuals with
chronic kidney disease,'' after ``other than subparagraph (E) of such
section (relating to smoking cessation agents),''.
<all>